InMed-logo-01
NASDAQ_Logo

Press Releases

Press Releases

InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules
InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
InMed to Present at Canaccord Genuity’s 5th Annual Global Cannabis Conference on May 11th, 2021
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
Displaying 1 - 10 of 176
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Science

Investor

About

Learn

© Copyright 2021 InMed Pharmaceuticals Inc.